3/31/2011

Cernostics has agreed to collaborate with Definiens to develop a multiplexed test that can diagnose cancer by looking at specific panels of fluorescence biomarkers. The company will develop the test using Definiens' Tissue Studio.

Full Story:
HealthImaging.com

Related Summaries